Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

Weight-loss drugs need to become cheaper, says AstraZeneca boss

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

The Guardian - UK · Feb 8, 2024

Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Barchart · Feb 7, 2024

Stock Market Today: Higher Close for Stocks, Palantir Soars on AI Optimism

While the main indexes made modest moves Tuesday, Palantir Technologies soared 30% after earnings.

Kiplinger · Feb 6, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

StockNews.com · Feb 5, 2024

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

StockNews.com · Feb 2, 2024

Weight loss injection to be made available in UK within weeks

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity

The Guardian - UK · Jan 25, 2024

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

StockNews.com · Jan 18, 2024

Read news from The Economist, FT, and more,
with one subscription

Iron Condor Alert: LLY Stock Could Net 40% In 4 Weeks

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

Barchart · Jan 10, 2024

Will weight loss drugs kill the fast food business?

Many firms see the dire forecasts as ‘overblown’ but they know they will have to adapt products to make ‘every bite counts’

The Guardian - UK · Jan 6, 2024

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

The Independent UK · Jan 4, 2024

Eli Lilly Launches Unique Website Connecting Patients to Obesity Care+

Eli Lilly launches LillyDirect, a one-of-a-kind website connecting patients seeking obesity treatment to doctors and its weight-loss drug. Streamlining hea...

Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of diabetes and obesity

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

Fortune · Jan 4, 2024

Eli Lilly Stock: Buy or Sell?

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Barchart · Jan 4, 2024

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Kiplinger · Jan 3, 2024

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · Dec 12, 2023

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

Inverse · Dec 6, 2023

Which Weight Loss Drug Is Best And Safest? Here’s What Sets Them Apart

Earlier this month, the FDA approved Eli Lilly's Zepbound, a drug similar to its diabetes drug Mounjaro but specifically advertised for weight loss.

International Business Times · Dec 4, 2023

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

The Independent UK · Dec 1, 2023

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune · Nov 29, 2023

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Barchart · Nov 17, 2023

Will Weight Loss Drugs be the Next Big Thing?

Several pharmaceutical companies are racing to develop obesity drugs and tap into a surge in consumer demand for the extremely profitable drugs. Sales of Eli Lilly’s (LLY ) diabetes drug Mounjaro, just approved by the U.S. Food and Drug Administration (FDA) for obesity in the U.S., hit $1.41 billion in...

Fortune · Nov 9, 2023

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

The Guardian - UK · Nov 9, 2023

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

Fortune · Nov 3, 2023

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Barchart · Nov 2, 2023

Stock Index Futures Climb on Hopes of End to Fed Rate Hikes, Apple Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.50%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.70% this morning as market participants weighed the possible peak of the Federal Reserve’s historic tightening campaign and looked ahead to an earnings report from Apple.

Barchart · Oct 26, 2023

Chart of the Day: Eli Lilly - Big Profits in Big Pharma

The Chart of the Day belongs to the pharmaceutical giant Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

1 … 25 26 27 28

Coverage From

People

Jerome Powell

3,485 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.